➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Johnson and Johnson
Mallinckrodt
Dow
AstraZeneca

Last Updated: January 24, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ASTEPRO

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for ASTEPRO

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00720382 A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis Completed Meda Pharmaceuticals Phase 3 2007-03-01 The purpose of this study is to determine if one allergy treatment (0.15% azelastine hydrochloride) is as safe as mometasone furoate (nasonex) alone.
NCT00783432 Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis Completed Meda Pharmaceuticals Phase 3 2006-07-01 The purpose of this study is to determine if Astepro Nasal Spray (0.1% azelastine hydrochloride) is as safe as Astelin Nasal Spray (0.1% azelastine hydrochloride)
NCT01368445 A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies Completed Meda Pharmaceuticals Phase 3 2006-08-01 The Purpose of this study is to evaluate the safety and efficacy of MP03-36 (0.15% azelastine hydrochloride)at dosages of 2 sprays per nostril once daily and 2 sprays per nostril twice daily in patients with seasonal allergic rhinitis.
NCT01880840 Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR Completed Novella Clinical Phase 4 2013-06-01 The purpose of this study is to compare the safety of 2 different doses of the investigational use of an allergy medication (Astepro Nasal Spray) in the treatment of allergic rhinitis (AR). This is an open-label study; that is, parent and child will know which group each is in.
NCT01880840 Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR Completed Meda Pharmaceuticals Phase 4 2013-06-01 The purpose of this study is to compare the safety of 2 different doses of the investigational use of an allergy medication (Astepro Nasal Spray) in the treatment of allergic rhinitis (AR). This is an open-label study; that is, parent and child will know which group each is in.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ASTEPRO

Condition Name

Condition Name for ASTEPRO
Intervention Trials
Seasonal Allergic Rhinitis 1
Perennial Allergic Rhinitis 1
Nonallergic Rhinitis 1
Chronic Allergic Rhinitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for ASTEPRO
Intervention Trials
Rhinitis 4
Rhinitis, Allergic 4
Rhinitis, Allergic, Seasonal 1
Common Cold 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for ASTEPRO

Trials by Country

Trials by Country for ASTEPRO
Location Trials
United States 51
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for ASTEPRO
Location Trials
California 3
Pennsylvania 3
Oklahoma 3
New Jersey 3
Colorado 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for ASTEPRO

Clinical Trial Phase

Clinical Trial Phase for ASTEPRO
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for ASTEPRO
Clinical Trial Phase Trials
Completed 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for ASTEPRO

Sponsor Name

Sponsor Name for ASTEPRO
Sponsor Trials
Meda Pharmaceuticals 4
Novella Clinical 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for ASTEPRO
Sponsor Trials
Industry 4
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Moodys
Baxter
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.